| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Charles P Connolly last filed a Form 4 in March 2018, as Director at MED. Charles P Connolly's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 41,374 shares of MED. The MED filings lean toward selling, a net 15,500 shares.
Charles P Connolly has 7 Form 4 filings on record from February 2015 to March 2018, all as Director at Medifast (MED), 2015–2018.
The 13 reported transactions were 4 stock awards, 3 option exercises, 2 open-market sales and 2 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $1.4M.
The largest open-market sale was 8,000 shares of MED at an average $90.95 on March 20, 2018, about $728K.
Shares as reported in the last Form 4 for each company; the most recent is from March 2018. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.